Journal
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
Volume 196, Issue 4, Pages -Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.ajog.2007.01.004
Keywords
endometrial carcinoma; estrogen receptor; GPR30; progesterone receptor; survival
Categories
Funding
- NCI NIH HHS [R01CA99908-1, CA11666, P30 CA118110, CA27469, R24 CA88339] Funding Source: Medline
- NCRR NIH HHS [P20 RR11830, S10 RR016918, S10 RR19287, 5M01 RR00997, 1 S10 RR14668] Funding Source: Medline
Ask authors/readers for more resources
OBJECTIVE: This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. STUDY DESIGN: Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. RESULTS: GPR30 correlated positively with epidermal growth factor receptor (P = .005), but negatively with progesterone (P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). CONCLUSION: GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available